Concise Report

Positive synovial vascularity in patients with low disease activity indicates smouldering inflammation leading to joint damage in rheumatoid arthritis: time-integrated joint inflammation estimated by synovial vascularity in each finger joint Abstract Objective. To investigate the relationship between synovial vascularity and joint damage progression in each finger joint of patients with RA under low disease activity during treatment with biologic agents. Methods. We studied 310 MCP and 310 PIP joints of 31 patients with active RA who were administered adalimumab (ADA) or tocilizumab (TCZ). Patients were examined with clinical and laboratory assessments. Power Doppler sonography was performed at baseline and at weeks 8, 20 and 40. Synovial vascularity was evaluated according to quantitative measurement. Hand and foot radiography was performed at baseline and at week 50. Results. Composite scores of the DAS with 28 joints and the Simplified Disease Activity Index (SDAI) were significantly decreased from baseline to week 8, being sustained at a low level by biologic agents during the observational period. MCP and PIP joints with positive synovial vascularity after week 8 showed more subsequent joint damage progression than joints without synovial vascularity throughout the follow-up. The changes in radiographic progression in these joints were independent of the sum of synovial vascu-larity from baseline to week 40 or the occasional occurrence of positive synovial vascularity. Conclusion. Smouldering inflammation reflected by positive synovial vascularity under low disease activity was linked to joint damage. The damage progressed irrespective of the severity of positive synovial vascularity. Even with a favourable overall therapeutic response, monitoring of synovial vascularity has the potential to provide useful joint information to tailor treatment strategies.

[1]  G. Wells,et al.  Celecoxib for rheumatoid arthritis. , 2017, The Cochrane database of systematic reviews.

[2]  G. Jamtvedt,et al.  Effectiveness of Nonpharmacological and Nonsurgical Interventions for Patients With Rheumatoid Arthritis: An Overview of Systematic Reviews , 2007, Physical Therapy.

[3]  D. Strachan,et al.  Rheumatoid arthritis association at 6q23 , 2007, Nature Genetics.

[4]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[5]  E. Brahn,et al.  Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis , 2007, Nature Clinical Practice Rheumatology.

[6]  P. Tugwell,et al.  Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  H. Putter,et al.  Effectiveness of the introduction of an International Classification of Functioning, Disability and Health-based rehabilitation tool in multidisciplinary team care in patients with rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[8]  P. Nilsson,et al.  Glycemic and Risk Factor Control in Type 1 Diabetes , 2007, Diabetes Care.

[9]  Esperanza Naredo,et al.  Longitudinal power Doppler ultrasonographic assessment of joint inflammatory activity in early rheumatoid arthritis: predictive value in disease activity and radiologic progression. , 2007, Arthritis and rheumatism.

[10]  B. Dijkmans,et al.  Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study. , 2006, Clinical and experimental rheumatology.

[11]  B. Charreau,et al.  The Adaptor Molecule Lnk Negatively Regulates Tumor Necrosis Factor-α-dependent VCAM-1 Expression in Endothelial Cells through Inhibition of the ERK1 and -2 Pathways* , 2006, Journal of Biological Chemistry.

[12]  H. Genant,et al.  Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis , 2006, Annals of Internal Medicine.

[13]  G. Gazelle,et al.  Coxibs Versus Combination NSAID and PPI Therapy for Chronic Pain: An Exploration of the Risks, Benefits, and Costs , 2006, The Annals of pharmacotherapy.

[14]  G. Burmester,et al.  Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis , 2005, Annals of the rheumatic diseases.

[15]  Wendy Thomson,et al.  Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. , 2005, Arthritis and rheumatism.

[16]  M. Ravid,et al.  Treatment of high-risk patients with diabetes: motivation and teaching intervention: a randomized, prospective 8-year follow-up study. , 2005, Journal of the American Society of Nephrology : JASN.

[17]  T. Pearson.  The epidemiologic basis for population-wide cholesterol reduction in the primary prevention of coronary artery disease. , 2004, The American journal of cardiology.

[18]  A. McMahon,et al.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial , 2004, The Lancet.

[19]  R. Saurenmann,et al.  A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. , 2004, Arthritis and rheumatism.

[20]  M. Bala,et al.  Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[21]  P. Shekelle.  The Appropriateness Method , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.

[22]  M. Tremblay,et al.  The role of protein tyrosine phosphatase 1B in Ras signaling , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[23]  L. Laine,et al.  Guidelines for the appropriate use of non‐steroidal anti‐inflammatory drugs, cyclo‐oxygenase‐2‐specific inhibitors and proton pump inhibitors in patients requiring chronic anti‐inflammatory therapy , 2004, Alimentary pharmacology & therapeutics.

[24]  J. Fries,et al.  Reduction in long-term functional disability in rheumatoid arthritis from 1977 to 1998:a longitudinal study of 3035 patients. , 2003, The American journal of medicine.

[25]  J. Kremer,et al.  Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. , 2003, Arthritis and rheumatism.

[26]  D. Lackland,et al.  Awareness, knowledge, and attitudes of older americans about high blood pressure: implications for health care policy, education, and research. , 2003, Archives of internal medicine.

[27]  A. Zwinderman,et al.  A randomized comparison of care provided by a clinical nurse specialist, an inpatient team, and a day patient team in rheumatoid arthritis. , 2002, Arthritis and rheumatism.

[28]  Sampath Prahalad,et al.  Increased prevalence of familial autoimmunity in simplex and multiplex families with juvenile rheumatoid arthritis. , 2002, Arthritis and rheumatism.

[29]  Rene Westhovens,et al.  COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. , 2002, Arthritis and rheumatism.

[30]  A. Zwinderman,et al.  Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. , 2001, The American journal of medicine.

[31]  S. Cavuto,et al.  Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology. , 2001, Clinical and experimental rheumatology.

[32]  J. Ware,et al.  Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[33]  A. Reiff,et al.  Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. , 2000, The New England journal of medicine.

[34]  M. Kimmey,et al.  Review article: nonsteroidal anti‐inflammatory drug‐associated gastrointestinal complications—guidelines for prevention and treatment , 1999, Alimentary pharmacology & therapeutics.

[35]  D. Felson,et al.  Preliminary definition of improvement in juvenile arthritis. , 1997, Arthritis and rheumatism.

[36]  J. Vandenbroucke,et al.  A randomized clinical trial of in-patient multidisciplinary treatment versus routine out-patient care in active rheumatoid arthritis. , 1996, British journal of rheumatology.

[37]  F. Breedveld,et al.  In-patient treatment for active rheumatoid arthritis: clinical course and predictors of improvement. , 1995, British journal of rheumatology.

[38]  J. Fries,et al.  Measurement of health status in children with juvenile rheumatoid arthritis. , 1994, Arthritis and rheumatism.

[39]  J. Cassidy,et al.  Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. , 1992, The New England journal of medicine.

[40]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[41]  R H Brook,et al.  A Method for the Detailed Assessment of the Appropriateness of Medical Technologies , 1986, International Journal of Technology Assessment in Health Care.

[42]  A. Cats,et al.  Measurement of disability in Dutch rheumatoid arthritis patients , 1984, Clinical Rheumatology.

[43]  Luis Llorens,et al.  Appendix , 1838, The Medico-Chirurgical Review.

[44]  A. Iagnocco,et al.  Ultrasound imaging for the rheumatologist VII. Ultrasound imaging in rheumatoid arthritis. , 2007, Clinical and experimental rheumatology.

[45]  F. Breedveld,et al.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. , 2006, Arthritis and rheumatism.

[46]  L. Laine.  Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary? , 2004, Reviews in gastroenterological disorders.

[47]  A. Zwinderman,et al.  Two-year follow-up of a randomized controlled trial of a clinical nurse specialist intervention, inpatient, and day patient team care in rheumatoid arthritis. , 2003, Journal of advanced nursing.

[48]  B. Burnand,et al.  The RAND/UCLA Appropriateness Method User's Manual , 2001 .

[49]  L. Jacobsson,et al.  Evaluation of a structured multidisciplinary day care program in rheumatoid arthritis. A similar effect in newly diagnosed and long-standing disease. , 1998, Scandinavian journal of rheumatology.